Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence

Rajman L, Chwalek K, Sinclair DA | Cell Metabolism | 2018 | Evidence: strong

Plain-language summary

Published 2018 in Cell Metabolism, this work by Rajman L and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

Critical review of NAD+ booster evidence quality
Identifies gaps between mouse and human data
Sinclair-authored - author NMN evangelist context

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the strong end of the evidence spectrum. Strong-tier human placebo-controlled trial data carries the most weight in our editorial framework - treat findings as actionable signal, but always pair with at least one replication. Findings here are most directly relevant to science decisions, with secondary relevance to benefits and compare. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

← Back to research index